Prostatitis medical therapy
|
Prostatitis Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Prostatitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Prostatitis medical therapy |
|
Risk calculators and risk factors for Prostatitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S[2], Usama Talib, BSc, MD [3], Anum Ijaz M.B.B.S., M.D.[4]
Overview
Antimicrobial therapy is indicated for acute and chronic prostatitis. Patients are generally treated in an outpatient setting unless severe disease (e.g. bacteremia) is suspected. Empirical therapy for both acute and chronic prostatitis includes monotherapy with either ciprofloxacin, levofloxacin, or TMP-SMX for at least 6 weeks. When culture results are obtained, antimicrobial therapy may be narrowed down to cover the causative pathogen more adequately. Addition of alpha blocker may be considered for the symptomatic management of bacterial prostatitis. Inflammatory prostatitis may be treated with NSAIDs, allopurinol, or cernilton. Patients not responding to medical therapy or without improvement in the fever after 36 hours of therapy should be investigated for an abscess or any other complication by using ultrasound, CT scan or an MRi.[1]
Medical Therapy
- The approach to the medical therapy for acute bacterial prostatitis is given below[2]
| History and Physical Examination | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ❑ Urine culture & Urinalysis: All patients ❑ Postvoid residual urine: If suspecting obstruction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mild to Moderately Ill ❑ TMP/SMX 160/800mg PO BID for 6 weeks OR ❑ Ciprofloxacin 500mg PO BID for 6 weeks | Seriously ill or Possible urosepsis ❑ Admit patient ❑ Ampicillin 2g IV q6h PLUS Gentamicin 5mg/kg q24h or 1.5mg/kg every eight hours untill afebrile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fever Persists or Not Improving ❑ Non contrast Pelvic CT with cuts through the prostate or ❑ Transrectal Ultrasonography | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative ❑ Modify antibiotics based on culture results | Positive ❑ Confirms diagnosis of Prostatic Abscess ❑ Consult urology for drainage | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Afebrile ❑ TMP/SMX 160/800mg PO BID for 6 weeks OR ❑ Ciprofloxacin 500mg PO BID for 6 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Chronic Prostatitis/Chronic Pelvic Pain Syndorme (CPPS)
- The approach towards medical therapy for chronic prostatitis (i.e chronic bacterial prostatitis) is as under[2]
| Chronic Prostatitis/CPPS | |||||||||||||||||||||||||||||||||
| Predominant urinary symptoms ❑ Alpha blocker | Combination of urinary and pain symptoms ❑ Finasteride ❑ Non pharmacological therapy ( e.g Biofeedback) ❑ Phytotherapy ❑ Consult Urology | Predominant pain symptoms ❑ Anti inflammatory drugs | |||||||||||||||||||||||||||||||
*Adopted from Ameican Family Physician[2]
Acute and Chronic Bacterial Prostatitis
- All patients with bacterial prostatitis (both acute and chronic) require empiric antimicrobial therapy until culture results are obtained.
- Addition of alpha blocker may be considered for the symptomatic management of bacterial prostatitis. Warm sitz baths may also be helpful.
- Generally, patients are treated in the outpatient setting. The indications to hospitalize patients[3] include the following:
- Sepsis or hemodynamic instability.
- Cannot tolerate oral antibiotics
- Monitoring when at-risk of decompensation (e.g. patients when major co-morbidities such as diabetes mellitus or HIV)
- Persistent fever or leukocytosis despite 48-72 hours of oral therapy.
- Recent prostate biopsy
- History of multidrug-resistant urinary pathogens
- Data on the efficacy of treatment regimens for prostatitis is limited. The choice of antibiotic depends on regional Enterobacteriaceae drug resistance and adequate drug penetration into the prostate tissue.[3]
- The duration of therapy is controversial. Due to limited penetration of antimicrobial agents into the prostate tissue, therapy for 6 weeks is recommended by experts to prevent development of chronic disease.[4]
- Patients with prostatitis with evidence of sexually transmitted infections (e.g. Chlamydia or N. gonorrhea) should be treated for both conditions.
Antimicrobial regimen
Acute Bacterial Prostatitis
- 1. Uncomplicated (with low risk of STD pathogens)[5]
- 1. Outpatient setting
- 1.1. Empirical therapy
- Preferred regimen (1): Ciprofloxacin 500 mg PO bid for 6 weeks OR Levofloxacin 500 mg PO qd for 6 weeks
- Preferred regimen (2): TMP-SMX 160 mg PO bid for 6 weeks
- Note: Nitrofurantoin, commonly used in lower urinary tract infections, should be avoided among men with prostatitis
- 1.2. Pathogen-directed therapy
- 1.2.1. Enterobacteriaceae (especially Escherichia coli)
- Preferred regimen: Ciprofloxacin 500 mg PO bid for 6 weeks OR Levofloxacin 500 mg PO qd for 6 weeks
- Alternative regimen: TMP-SMX DS (160 mg TMP) bid for 6 weeks
- 1.2.2. Enterococcus species
- Preferred regimen: Amoxicillin 500 mg PO q8h for 6 weeks OR Vancomycin 15 mg/kg q12h for 6 weeks
- Alternative regimen: Levofloxacin 750 PO qd for 6 weeks OR Linezolid 600 mg q12h for 6 weeks
- Note (1): Use intravenous therapy if systemically ill; switch to oral therapy when stable
- Note (2): Amoxicillin is not active against Enterococcus faecium
- 1.2.3. Pseudomonas aeruginosa
- Preferred regimen: Ciprofloxacin 400 mg tid for 6 weeks
- Alternative regimen: Piperacillin-tazobactam 4.5 g IV q6h for 6 weeks
- 1.2.4. Methicillin sensitive Staphylococcus spp.
- Preferred regimen: Cephalexin 500 mg PO q6h for 6 weeks OR Dicloxacillin 500 mg PO q6h for 6 weeks
- 1.2.5. Healthcare associated
- Preferred regimen: Ertapenem 1 g IV qd for 6 weeks OR Cefepime 2g IV q12h for 6 weeks OR Imipenem 500 mg IV q6h for 6 weeks OR Cephalexin 500 mg PO q6h for 6 weeks OR Ceftriaxone 1 g IV qd for 6 weeks
- 2. Hospitalization
- 2.1. Empirical therapy
- Preferred regimen: (Ciprofloxacin 400 mg IV bid for 6 weeks OR Levofloxacin 500-750 mg IV qd for 6 weeks) ± (Gentamicin 5 mg/kg IV qd for 6 weeks OR Tobramycin 5 mg/kg IV qd for 6 weeks)
- Alternative regimen: Ceftriaxone 1 g IV qd for 6 weeks ± (Gentamicin 5 mg/kg IV qd for 6 weeks OR Tobramycin 5 mg/kg IV qd for 6 weeks)
- Note: Avoid gentamicin/tobramycin among patients with impaired renal function
- Patients who respond to IV antibiotics should be converted to oral therapy within 1-2 days of symptomatic improvement
- 2.2. Pathogen-directed therapy
- 2.2.1. Enterococcus species
- Preferred regimen: Ampicillin 2 g IV q6h for 6 weeks
- Note: Ampicillin is not active against Enterococcus faecium
- 2.2.2. Methicillin sensitive Staphylococcus spp.
- Preferred regimen: Nafcillin 2g IV q4h-q6h for 6 weeks
- Preferred regimen: Vancomycin 15-20 mg/lg/dose q8h-q12h for 6 weeks
- Note: Each vancomycin dose should not exceed 2 g
Chronic Bacterial Prostatitis
- 1. Fluoroquinolone-susceptible organisms
- Preferred regimen: Ciprofloxacin 500 mg PO q12h for at least 6 weeks OR Levofloxacin 500 mg PO qd for at least 6 weeks
- Alternative regimen: TMP-SMX single dose DS bid for at least 6 weeks
- 2. Chlamydia spp.
- Preferred regimen: Azithromycin 500 mg PO qd for 3 days/week for a total of 3 weeks
- Alternative regimen: Doxycycline 100 mg PO bid for 4-6 weeks
Treatment of Sexual Partners
- Treatment of sexual partners is not necessary in either acute or chronic prostatitis when sexually transmitted infections are ruled out.
Follow-up
- Patients may be re-evaluated at 7 days following the initiation of therapy. Patients should also be re-evaluated monthly during the administration of antimicrobial therapy regimen.
- Patients generally report symptomatic improvement at day 2-day 6 of antimicrobial therapy. Patients who fail to respond to antimicrobial therapy should be evaluated for either resistance or development of prostate abscess.
- A urine culture may be obtained at day 7 of antimicrobial therapy. A negative culture is associated with good prognosis, whereas positive cultures are associated with development of chronic disease and usually warrant the administration of alternative antibiotic regimens.
- Following recovery, patients should be evaluated to determine possible causes of prostatitis, including structural abnormalities of the urinary tract.
Chronic Prostatitis/Chronic Pelvic Pain Syndorme (CPPS)
Role of Antibiotics
Routine antibiotic therapy is not recommended for chronic prostatitis/chronic pelvic pain syndrome in the absence of documented bacterial infection.[7]
Multiple randomized trials and meta-analyses demonstrate that antibiotics provide no clinically meaningful improvement in symptom severity compared with placebo when cultures are negative. The potential benefits observed in some studies do not meet thresholds for minimal clinically important differences.[8],[9],[10], [11]
To reduce antimicrobial resistance and adverse effects, antibiotics should be reserved only for patients with positive blood culture.[12]
Recommended Medical Management
Management of CP/CPPS should be individualized and based on symptom profile, with shared decision-making. First-line medical therapy for patients with lower urinary tract symptoms includes:
- α-adrenergic blockers (e.g., tamsulosin, alfuzosin)
Patients without symptom improvement after 4–6 weeks of α-blocker therapy should discontinue treatment.[13]
Adjunctive therapies may include:
- Non-opioid analgesics ( Acetaminophen or ibuprofen for 4-6 weeks).[13]
- Neuropathic pain agents (e.g. pregabalin)[14]
- Anti-inflammatory medications
- Phytotherapies ( e.g. quercetin)[15]
- Pentosan Polysulfate. [16]
Multimodal Approach
A multimodal treatment strategy may be beneficial, particularly for patients with:[12]
- Pelvic floor myalgia
- Psychosocial distress (e.g., anxiety, depression)
- Nonurologic chronic pain syndromes
Referral for pelvic floor physical therapy, mental health evaluation, or pain management may be appropriate.
Opioid analgesics should be avoided due to lack of evidence of benefit and risk of harm.
Summary of Oral Therapies for Chronic Prostatitis / Chronic Pelvic Pain Syndrome[12]
| Therapy | Examples | Mechanism of action | Adverse effects |
| Antibioticsᵃ | Levofloxacin 500 mg daily
Ciprofloxacin 500 mg twice a day |
Possible anti-inflammatory effect or treatment of undetected organisms | Levofloxacin and ciprofloxacin: [17]
Tendinopathy/tendon rupture (0.14%–0.4%) Nausea (3%–7%), diarrhea (5%), vomiting (2%–5%) Headache (6%) QT-interval prolongation Contraindicated with aneurysm |
| α-Blockers | Tamsulosin 0.4 mg daily
Alfuzosin 10 mg daily |
Relaxation of prostatic and bladder neck smooth muscle | Tamsulosin and Alfuzosin:
Dizziness, orthostatic hypotension (6%–17%) Ejaculatory dysfunction (up to 18%) |
| Anti-inflammatory drugs | NSAIDs: diclofenac 50 mg 3 times a day, ibuprofen 400 mg 4 times a day | Reduction in prostatic inflammation | NSAIDs: nephrotoxicity (1%–5%),
peptic ulcer disease, platelet inhibition. |
| Pregabalin | Pregabalin 50–200 mg 3 times a day | Neuromodulation of pain pathways | Pregabalin:
Dizziness (30%) Sedation (23%) Weight gain (9%) Blurred vision (7%) Peripheral edema (6%) Seizure with rapid discontinuation Suicidal thoughts/behavior (0.4%) |
| Pentosan polysulfate | Pentosan polysulfate 100 mg 3 times a day | Protective effect on bladder epithelium, possible anti-inflammatory | Pentosan polysulfate:
Reversible alopecia (4%) Nausea (4%), diarrhea (4%) Vision change secondary to macular eye disease with long-term use (0.6%–5.4%) |
| Phytotherapy | Quercetin 500 mg twice a day
Pollen extract RCT: 2 capsules (each containing 63 mg extract) every 8 h |
Possible anti-inflammatory effect or smooth muscle relaxation | Quercetin: headache (3%), rash (3%), paresthesia (3%)
Pollen extract: gastrointestinal upset (1%) |
Abbreviations: NIH-CPSI = National Institutes of Health Chronic Prostatitis Symptom Index; NSAID = nonsteroidal anti-inflammatory drug; RCT = randomized clinical trial. ᵃ High-quality evidence does not support that antibiotics have a clinically important effect on symptoms, and guidelines do not recommend antibiotics.
Non-Bacterial Prostatitis
- Patients with non-bacterial causes of prostatitis should be evaluated thoroughly for structural abnormalities and malignancies.
- Patients with inflammatory prostatitis and no evidence of bacterial prostatitis may be treated with NSAIDs and/or cernilton and/or allopurinol.
- The following drugs have been reported to be effective in the symptomatic managemnet of patients with chronic disease:
- Irritation:
- Pain:
References
- ↑ J. Curtis Nickel (2003). "Recommendations for the evaluation of patients with prostatitis". World journal of urology. 21 (2): 75–81. doi:10.1007/s00345-003-0328-1. PMID 12684835. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 2.2 Sharp VJ, Takacs EB, Powell CR (2010). "Prostatitis: diagnosis and treatment". Am Fam Physician. 82 (4): 397–406. PMID 20704171.
- ↑ 3.0 3.1 Brede CM, Shoskes DA (April 2011). "The etiology and management of acute prostatitis". Nat Rev Urol. 8 (4): 207–12. doi:10.1038/nrurol.2011.22. PMID 21403661.
- ↑ Wagenlehner FM, Weidner W, Naber KG (2007). "Therapy for prostatitis, with emphasis on bacterial prostatitis". Expert Opin Pharmacother. 8 (11): 1667–74. doi:10.1517/14656566.8.11.1667. PMID 17685884.
- ↑ 5.0 5.1 Lipsky BA, Byren I, Hoey CT (2010). "Treatment of bacterial prostatitis". Clin Infect Dis. 50 (12): 1641–52. doi:10.1086/652861. PMID 20459324.
- ↑ Schaeffer AJ, National Institute of Diabetes and Digestive and Kidney Diseases of the US National Institutes of Health (2004). "NIDDK-sponsored chronic prostatitis collaborative research network (CPCRN) 5-year data and treatment guidelines for bacterial prostatitis". Int J Antimicrob Agents. 24 Suppl 1: S49–52. doi:10.1016/j.ijantimicag.2004.02.009. PMID 15364307.
- ↑ Lai HH, Pontari MA, Argoff CE, Bresler L, Breyer BN, Chou R, Clemens JQ, De EJ, Doiron RC, Johnson D, Kirkby E, MacDonald SM, Osborne JH, Parekattil SJ, Shelly B (August 2025). "Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach". J Urol. 214 (2): 116–126. doi:10.1097/JU.0000000000004564. PMID 40243110 Check
|pmid=value (help). - ↑ Thakkinstian A, Attia J, Anothaisintawee T, Nickel JC (October 2012). "α-blockers, antibiotics and anti-inflammatories have a role in the management of chronic prostatitis/chronic pelvic pain syndrome". BJU Int. 110 (7): 1014–22. doi:10.1111/j.1464-410X.2012.11088.x. PMID 22471591.
- ↑ Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, Garrote V, Vietto V (April 2020). "Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome: a Cochrane systematic review". BJU Int. 125 (4): 490–496. doi:10.1111/bju.14988. PMID 31899937.
- ↑ Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, Whelan JS, Jackson JL, Dimitrakoff JD (2012). "Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis". PLoS One. 7 (8): e41941. doi:10.1371/journal.pone.0041941. PMC 3411608. PMID 22870266.
- ↑ Zhu Y, Wang C, Pang X, Li F, Chen W, Tan W (May 2014). "Antibiotics are not beneficial in the management of category III prostatitis: a meta analysis". Urol J. 11 (2): 1377–85. PMID 24807747.
- ↑ 12.0 12.1 12.2 Borgert BJ, Wallen EM, Pham MN (September 2025). "Prostatitis: A Review". JAMA. 334 (11): 1003–1013. doi:10.1001/jama.2025.11499. PMID 40788632 Check
|pmid=value (help). - ↑ 13.0 13.1 Rees J, Abrahams M, Doble A, Cooper A (October 2015). "Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline". BJU Int. 116 (4): 509–25. doi:10.1111/bju.13101. PMC 5008168. PMID 25711488.
- ↑ Pontari MA, Krieger JN, Litwin MS, White PC, Anderson RU, McNaughton-Collins M, Nickel JC, Shoskes DA, Alexander RB, O'Leary M, Zeitlin S, Chuai S, Landis JR, Cen L, Propert KJ, Kusek JW, Nyberg LM, Schaeffer AJ (September 2010). "Pregabalin for the treatment of men with chronic prostatitis/chronic pelvic pain syndrome: a randomized controlled trial". Arch Intern Med. 170 (17): 1586–93. doi:10.1001/archinternmed.2010.319. PMC 3767281. PMID 20876412.
- ↑ Shoskes DA, Zeitlin SI, Shahed A, Rajfer J (December 1999). "Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial". Urology. 54 (6): 960–3. doi:10.1016/s0090-4295(99)00358-1. PMID 10604689.
- ↑ Nickel JC, Forrest JB, Tomera K, Hernandez-Graulau J, Moon TD, Schaeffer AJ, Krieger JN, Zeitlin SI, Evans RJ, Lama DJ, Neal DE, Sant GR (April 2005). "Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study". J Urol. 173 (4): 1252–5. doi:10.1097/01.ju.0000159198.83103.01. PMID 15758763.
- ↑ Khaliq Y, Zhanel GG (June 2003). "Fluoroquinolone-associated tendinopathy: a critical review of the literature". Clin Infect Dis. 36 (11): 1404–10. doi:10.1086/375078. PMID 12766835.